Anti-platelet therapy in coronary heart disease
A new, produced in Russia, form of acetylsalicylic acid (ASA), Askolong, could substantially improve patients’ compliance to long-term anti-aggregant therapy. Oral Askolong (12,5 mg) is absorbed via oral mucosa and does not cause gastrointestinal adverse effects, which are the main reason for treatm...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2023 |